BioTuesdays

Tag - Stifel

Alphatec Spine Logo

Stifel starts Alphatec at buy; PT $13

Stifel initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $13 price target. The stock closed at $9.88 on Oct. 19. Alphatec engages in design, development, and marketing of spinal fusion...

SeaSpine Holdings

Stifel starts SeaSpine at buy; PT $22

Stifel launched coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and price target of $22. The stock closed at $14.97 on Oct. 19. “After several years of uneven performance post the 2015 spin-out from...

Dyne Logo

Stifel starts Dyne Therapeutics at buy; PT $29

Stifel initiated coverage of Dyne Therapeutics (NASDAQ:DYN) with a “buy” rating and $29 price target. The stock closed at $18.64 on Oct. 9. “We view Dyne as an emerging leader in the neuromuscular space, and our...

Nurix Logo

Stifel starts Nurix Therapeutics at buy; PT $34

Stifel initiated coverage of Nurix Therapeutics (NASDAQ:NRIX) with a “buy” rating and $34 price target. The stock closed at $27 on Aug. 17. Nurix is a soon-to-be-clinical-stage company focused on the discovery...

CymaBay

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

Radius Health Logo

Stifel starts Radius Health at hold; PT $20

Stifel initiated coverage of Radius Health (NASDAQ:RDUS) with a “hold” rating and $20 target price. The stock closed at $17.18, up $1.43, on April 23. Analyst Annabel Samimy writes that Radius established a solid...

Cue Biopharma Logo

Stifel starts Cue Biopharma at buy; PT $21

Stifel initiated coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $21 price target. The stock closed at $16.60, up $1.53, on April 8. “We believe the Immuno-STAT platform from which the company’ wholly...

Molecular Templates

Stifel starts Molecular Templates at buy; PT $19

Stifel initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $19 price target. The stock closed at $13.29 on March 24. “We believe the engineered toxin body technology from which Molecular’s...

AdaptHealth

Stifel starts AdaptHealth at buy; PT $17

Stifel initiated coverage of AdaptHealth (NASDAQ:AHCO) with a “buy” rating and $17 price target. The stock closed at a 52-week high of $13 on Jan. 30. “AdaptHealth is a unique asset poised to capitalize on an ongoing...